Rennova Health, Inc. announced that it has entered into a purchase agreement for a private placement of 4,400 shares of series O preferred stock at a price of $909.090909 each share for gross proceeds of $4,000,000 on May 10, 2021. The shares will bear a fixed dividend of 10% per annum. Each share of the series O preferred stock is convertible into shares of the company’s common stock. The conversion price is equal to 90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date. The minimum investment accepted from any outside investor is $1. The company will receive the funding in tranches. On the same day, the company issued 1,100 shares for gross proceeds of $1,100,000 in its first tranche. The company received $1,000,000 in its first tranche from 2 investors pursuant to Regulation D.